We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures
News

Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures

Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures
News

Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Zytoprotec has announced that it has raised EUR 2 million in financing from new investor Baxter Ventures towards a EUR 4 million Series A financing.

Baxter Ventures is an investment initiative established by Baxter International in 2011 to invest up to USD 200 million in promising companies.

As a result of the financing Norbert Riedel, Ph.D., Baxter’s Chief Science and Innovation Officer will join Zytoprotec’s Supervisory Board.

Zytoprotec’s most advanced product, PD-protec™, is a next-generation solution for peritoneal dialysis (PD) designed to actively protect abdominal cells.

The peptide used as the cytoprotective component of PD-protec™ is patent-protected by Zytoprotec. The product has completed a Phase I/II trial in 2012 and a Phase II trial is planned to commence in early 2013.

“We are very pleased to add Baxter to our investor base, given the company’s longstanding expertise and leadership in PD therapy”, Peter C. Weilguni, Chief Executive Officer of Zytoprotec, commented.

Weilguni continued, “We welcome Dr. Riedel to the Board of our Company as we are preparing PD-protec™ for a Phase II clinical trial.”

“Zytoprotec offers an exciting technology opportunity to protect the peritoneal membrane”, commented Norbert Riedel, Ph.D, Baxter’s Chief Science and Innovation Officer.

Riedel continued, “A peritoneal dialysis solution that holds the potential to prolong treatment time on PD would bring significant benefits to patients with kidney disease.”

Advertisement